Cheng Ying

Cheng Ying (; December 1962 – July 2025) was a Chinese oncologist, physician-scientist, and hospital administrator. She was the director of Jilin Cancer Hospital and a leading figure in cancer research in China, particularly in the field of lung cancer. Her work as a principal investigator for major clinical trials, including studies funded by AstraZeneca, earned her international recognition.

Early life and education Cheng Ying was born in 1962. She graduated from Bethune Medical University (now part of Jilin University) in July 1986, embarking on a career in medicine that would span nearly four decades.

Cheng was a vice president of the Chinese Society of Clinical Oncology (CSCO) and chairwoman of its Small Cell Lung Cancer Committee. She was also vice-chairman of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association.

Cheng was the lead principal investigator of the ADRIATIC study, a global clinical trial funded by AstraZeneca. The results, published in The New England Journal of Medicine in September 2024, found that durvalumab improved overall survival and progression-free survival in patients with limited-stage SCLC following chemoradiotherapy.

Death Cheng died suddenly between 2 and 9 July 2025 at the age of 62. The cause of death was not publicly announced. Her last public appearance was reportedly on 10 May 2025, at the annual meeting of the small-cell carcinoma committee of the Chinese Anti-Cancer Association.